A popular drug used for diabetes and weight loss may also help protect the brain. That’s the key message from a new study ...

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

Premature permanent discontinuation of oral semaglutide or placebo occurred in 1309 participants (27.1%) in the oral semaglutide group and in 1373 participants (28.5%) in the placebo group (Fig. S3B).

At just three months, before dose titration was over, participants on semaglutide had a noted decreased risk for stroke, heart attack, or cardiovascular death, with additional benefits at six months.

Taking semaglutide may lead to a slight increase in heart rate — typically by two to three beats per minute, based on trials sponsored by Novo Nordisk using 0.5 and 1 mg doses of semaglutide.

At 3 years, rates of the composite outcomes increased to 5.9% and 6.9% for those treated with semaglutide and empagliflozin, respectively, corresponding to an HR of 0.89 (95% CI, 0.78-1.02).

The researchers analyzed data from 16 million patients from a health claims database, narrowing it down to 1,926 semaglutide users and 1,348 users of bupropion-naltrexone, another type of weight ...

A recent study linked GLP-1 (glucagon-like peptide-1) agonists — the class of drugs that includes semaglutides — to an increased risk of hair loss. Here's what you should know.